[Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Department of Internal Medicine III, Kurume University School of Medicine.
Sho-ichi
S
Yamagishi
Tsutomu
T
Imaizumi
D000818:Animals; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000209:etiology; D017127:Glycation End Products, Advanced / Q000096:biosynthesis*; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects; D011733:Pyridoxamine / Q000494:pharmacology / Q000627:therapeutic use*; D013830:Thiadiazoles / Q000494:pharmacology / Q000627:therapeutic use*; D013831:Thiamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*; D053778:Thiazolidines
D017127:Glycation End Products, Advanced; D006146:Guanidines; C105739:OPB 9195; D013830:Thiadiazoles; D013844:Thiazoles; D053778:Thiazolidines; D011733:Pyridoxamine; C406794:alagebrium; C004479:pimagedine; D013831:Thiamine; C013835:benphothiamine